tiprankstipranks
Agile Therapeutics price target lowered to $3 from $5 at H.C. Wainwright
The Fly

Agile Therapeutics price target lowered to $3 from $5 at H.C. Wainwright

H.C. Wainwright analyst Oren Livnat lowered the firm’s price target on Agile Therapeutics to $3 from $5 and keeps a Buy rating on the shares. Heading into 2023, the analyst is "encouraged" by continued Twirla growth trends despite the company dramatically reducing commercial spending, and the apparent strong Q4 follow-through of its non-retail channel, namely Planned Parenthood. Livnat is "hopeful that with a couple quarters of robust" Twirla performance through Q4, and increasing clarity around Planned Parenthood reorder patterns, Agile "may soon be in a position to potentially provide investors more forward visibility on Twirla sales ramp." The analyst cites increased assumed dilution due to market conditions and the stock price for the target drop.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on AGRX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles